Verition Fund Management
AKRO

Verition Fund Management’s Akero Therapeutics AKRO Stock Holding History

Verition Fund Management’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-18,425
Closed -$875K – 3479
2025
Q3 		$875K Buy
+18,425
New +$892K ﹤0.01% 2627
2025
Q2 		– Sell
-18,417
Closed -$746K – 3613
2025
Q1 		$746K Sell
18,417
-15,018
-45% -$637K ﹤0.01% 2331
2024
Q4 		$930K Buy
+33,435
New +$1.01M ﹤0.01% 2099
2024
Q3 		– Sell
-9,256
Closed -$217K – 3155
2024
Q2 		$217K Buy
+9,256
New +$198K ﹤0.01% 2544
2023
Q2 		– Sell
-5,360
Closed -$205K – 2178
2023
Q1 		$205K Buy
+5,360
New +$239K ﹤0.01% 1751

Other funds holding AKRO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Verition Fund Management's AKRO Position: Q4 2025 in Review

Verition Fund Management sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 18,425 shares — an estimated $875K sold.

Verition Fund Management first reported a position in AKRO in Q1 2023 and held it in 5 quarters. The position peaked at $930K in Q4 2024. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • Verition Fund Management reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Verition Fund Management sold 18,425 Akero Therapeutics shares in Q4 2025, an estimated $875K.
  • Verition Fund Management first reported a position in Akero Therapeutics in Q1 2023 and held it in 5 quarters.
  • Verition Fund Management's Akero Therapeutics position peaked at $930K in Q4 2024.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Verition Fund Management's 13F filing for Q4 2025, filed 13 Feb 2026.